Navigation Links
FirstMark's Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
Date:2/16/2012

SAN DIEGO, Feb. 16, 2012 /PRNewswire-iReach/ -- FirstMark today announced the completion of the clinical study for the multiple biomarker cardiovascular blood test PREvent. These clinical results demonstrate the extraordinary effectiveness of the test to predict near term (2-3 years) risk of myocardial infarction and death in patients with suspected or confirmed, insignificant or significant CAD. The clinical study and final data was well received in an oral presentation, An Aggregate of 3 Biomarkers Predict Very High Risk of Acute Myocardial Infarction and Death, by Dr. Stephen E. Epstein, Executive Director of the Cardiovascular Research Institute, MedStar Health Research Institute, at the Cardiovascular Research Technologies 2012 Conference in Washington D.C. on February 6, 2012.

The study revealed superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal.  The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

"We are very pleased about the outstanding data results, and the promise PREvent brings to cardiovascular medicine," said Thomas Silberg, President and CEO of GenWay Biotech. "It's important for physicians to have a simple method to detect patients at greatest risk of near term MI. Ideally this information will lead to the most aggressive therapy, compliance and management in hope to eliminate MI and reduce death."

About the Study
The study was based on long-term research that reveals that there are multiple factors invo
'/>"/>

SOURCE GenWay Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
2. EMD Serono Launches Landmark Patient Registry for Egg Freezing
3. SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program
4. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
5. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
6. Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
7. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
8. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
9. Dune Medicals MarginProbeâ„¢ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed to be ... (including shares of unvested restricted stock). On June 29, 2015, the last trading day ... shares reported on the OTCBB was $2.29 per share. , The tender offer will ...
(Date:6/30/2015)... -- The Dr. Samadi Prostate Cancer Center in New ... of new genetic testing methods for men with an elevated ... Dr. Samadi,s Prostate Cancer Center ... risk and optimizing the diagnosis of prostate cancer, both pre-biopsy ... offer these revolutionary genetic tests to men with an elevated ...
(Date:6/29/2015)...   Pharnext SAS today announced that data related ... of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four ... Society (PNS) Biennial Meeting at the Quebec Congress Center in ... July 2, 2015. At Poster Viewing Session 4, ... to 7p.m. EDT: Poster 23: "A Meta-Analysis ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... tracking the number and dimension of particles or droplets as they ... are specific and possibly unique, changes that are of critical importance ... provide you with the knowledge, information and best practices you need ... ...
... of a new system to study crystallization processes for ... name,Crystalline. , The Crystalline has ... to learn as much as possible about a drug ... "Avantium is proud to launch its next system ...
... Institute have discovered a new method for controlling ... potentially one step closer to realizing the mass ... sheet of carbon, was discovered in 2004 and ... silicon as the fundamental building blocks of nanoelectronics. ...
Cached Biology Technology:Maximize Data Analysis with METTLER TOLEDO FBRM 2Avantium Launches the Crystalline, a New Parallel System for Crystallization Research 2Light-speed nanotech: Controlling the nature of graphene 2
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... vast majority of patients who had a successful ... need mitral valve surgery three years after their ... of the left ventricle (commonly known as reverse ... the Cardiovascular Research Foundations (CRF) nineteenth annual Transcatheter ...
... D.C. October 24, 2007 - The U.S. Senate ... Appropriations Bill (S.1710), including a provision that directs the ... Access Policy by requiring rather than requesting participation by ... House Appropriations Bill, which contains a similar provision, in ...
... Germany-October 24, 2007-Harvard University,s Office of Technology Development ... jointly establish the BASF Advanced Research Initiative. ... and Applied Sciences (SEAS) the initiative will benefit ... throughout the University. Set up as a ...
Cached Biology News:New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Mandate for public access to NIH-funded research poised to become law 2BASF and Harvard University announce extensive research collaboration 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Pack provides optimized blocking and wash ... Clarifier: Ready-to-use wash solutions have been ... Coated Slides for Microarrays (Product Code ... Buffer: 1L • Microarray Post Hybridization ...
Biology Products: